Moorfields Eye Hospital

Running trials

• Recruiting

  An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

  NCT07392255· Phase 1/2· Complement Therapeutics· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  NCT07144137· Complement Therapeutics· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Phase 3· Belfast Health and Social Care Trust· Source

• Active, not recruiting

  A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

  NCT06646289· Phase 2· MeiraGTx Ocular UK Ltd· Source

• Active, not recruiting

  A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

  NCT06248619· Phase 3· Amgen· Source

• Recruiting

  Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

  NCT06591793· Phase 1/2· AAVantgarde Bio Srl· Source

• Enrolling by invitation

  Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - SUMMIT (Part 2)

  NCT06682455· University of Southampton· Source

• Recruiting

  A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

  NCT06435000· Splice Bio· Source

• Active, not recruiting

  A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

  NCT04850118· Phase 2/3· Beacon Therapeutics· Source

• Active, not recruiting

  Oral N-acetylcysteine for Retinitis Pigmentosa

  NCT05537220· Phase 3· Johns Hopkins University· Source

• Recruiting

  Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

  NCT05589714· Jaeb Center for Health Research· Source

• Active, not recruiting

  Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

  NCT05610319· Phase 4· McMaster University· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

  NCT05407636· Phase 3· AbbVie· Source

• Active, not recruiting

  Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

  NCT04765345· Jaeb Center for Health Research· Source

• Recruiting

  Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

  NCT04663750· Phase 3· King's College Hospital NHS Trust· Source

• Active, not recruiting

  Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  NCT04794101· Phase 3· MeiraGTx Ocular UK Ltd· Source

• Active, not recruiting

  Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE

  NCT04269304· University of Southampton· Source

• Active, not recruiting

  Development of Novel Clinical Endpoints in Intermediate AMD

  NCT03349801· Frank G. Holz· Source

• Active, not recruiting

  Rate of Progression in USH2A-related Retinal Degeneration

  NCT03146078· Jaeb Center for Health Research· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration5 recruiting
• Diabetic eye disease2 recruiting
• Retinitis pigmentosa2 recruiting

Closed trials

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

  NCT05978622· AbbVie· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

  NCT05797896· Complement Therapeutics· Source

• Completed

  Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

  NCT04722991· Phase 2· Bayer· Source

• Completed

  Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  NCT04671433· Phase 3· MeiraGTx Ocular UK Ltd· Source

• Terminated

  FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

  NCT03846193· Phase 1/2· Gyroscope Therapeutics Limited· Source

• Completed

  Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

  NCT03584165· Phase 3· NightstaRx Ltd, a Biogen Company· Source

• Completed

  Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

  NCT03364153· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Completed

  Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

  NCT03349242· MeiraGTx UK II Ltd· Source

• Completed

  Long-term Follow-up Gene Therapy Study for RPGR- XLRP

  NCT04312672· MeiraGTx Ocular UK Ltd· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Glaucoma43 works · 0 trials
• Macular degeneration34 works · 12 trials
• Diabetic eye disease28 works · 7 trials
• Retinitis pigmentosa13 works · 12 trials